Environmental arsenic exposure and sputum metalloproteinase concentrations

Environmental Research

Volumn 102, Issue 3, 2006, Pages 283-290

  Josyula, Arun B ^a   Poplin, Gerald S ^a   Kurzius Spencer, Margaret ^a   McClellen, Hannah E ^a   Kopplin, Michael J ^a   Stürup, Stefan ^b   Clark Lantz, R ^a   Burgess, Jefferey L ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b DARTMOUTH COLLEGE   (United States)

Author keywords

Arsenic; Lung inflammation; Matrix metalloproteinase; MMP 9; TIMP 1

Indexed keywords

ARSENIC; METALLOPROTEINASE;

ARSENIC; BIOMARKER; CANCER; DRINKING WATER; ENZYME ACTIVITY; MUCUS; POLLUTION EXPOSURE; URINE;

ADULT; AGED; ARTICLE; ASTHMA; CONTROLLED STUDY; ENVIRONMENT; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; SMOKING; SPUTUM; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ARIZONA; ARSENIC; BIOLOGICAL MARKERS; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METHYLATION; MIDDLE AGED; PNEUMONIA; SPUTUM; TISSUE INHIBITOR OF METALLOPROTEINASE-1; WATER POLLUTANTS, CHEMICAL; WATER SUPPLY;

AJO; ARIZONA; NORTH AMERICA; TUCSON; UNITED STATES;

EID: 33746915331     PISSN: 00139351     EISSN: 10960953     Source Type: Journal    
DOI: 10.1016/j.envres.2006.01.003     Document Type: Article

References (53)

1. Achanzar W.E., Brambila E.M., Diwan B.A., Webber M.M., and Waalkes M.P. Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J. Natl. Cancer Inst. 94 (2002) 1888-1891
2. Andrew A.S., Barchowsky A., Davey J.C., Soucy N.V., Mayka D.D., Lantz R.C., Hays A., and Hamilton J.H. In vivo exposure to drinking water arsenic modifies expression of genes in the mouse lung. Toxicol. Sci. 78 S1 (2004) 145
3. Bates M.N., Smith A.H., and Cantor K.P. Case-control study of bladder cancer and arsenic in drinking water. Am. J. Epidemiol. 141 (1995) 523-530
4. Burgess J.L., Nanson C.J., Gerkin R., Witten M.L., Hysong T.A., and Lantz R.C. Rapid decline in sputum IL-10 concentration following occupational smoke exposure. Inhal. Toxicol. 14 (2002) 133-140
5. Butler G.S., Apte S.S., Willenbrock F., and Murphy G. Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions. J. Biol. Chem. 16,274 16 (1999) 10846-10851
6. Chen C.J., Wu M.M., Lee S.S., Wang J.D., Cheng S.H., and Wu H.Y. Atherogenicity and carcinogenicity of high artesian well water. Atherosclerosis 8 15 (1988) 452-460
7. Chen C.J., Chen C.W., Wu M.M., and Kuo T.L. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br. J. Cancer 66 (1992) 888-892
8. Chowdhury, U.K., Chakraborti, D., Rahman, M.M., Paul, K., Lodh, D., Chanda, C.R., Roy, S., Quamruzzaman, Q., Skaran, N.C., Roychowdhury, T., Uchino, T., 2002. Speciation of arsenic of arsenic compounds [As(iii), As(v), MMA, DMA] in human urine from an arsenic exposed area in Bangladesh. In: Fourth International Conference 2002 on Arsenic Contamination of Ground Water in Bangladesh: Cause, Effect and Remedy.
9. Cooper K.L., Myers T.A., Rosenberg M., Chavez M., and Hudson L.G. Roles of mitogen activated protein kinases and EGF receptor in arsenite-stimulated matrix metalloproteinase-9 production. Toxicol. Appl. Pharmacol. 200 3 (2004) 177-185
10. Declaux D., Delacourt C., d'Ortho M., Boyer V., Lafuma C., and Harf A. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am. J. Respir. Cell. Mol. Biol. 14 (1996) 288-295
11. Devarajan P., Johnston J.J., Ginsberg S.S., Van Wart H.E., and Berliner N. Structure and expression of neutrophil gelatinase cDNA. Identity with type IV collagenase from HT1080 cells. J. Biol. Chem. 267 (1992) 25228
12. EPA http://www.epa.gov/superfund/resources/soil/appd_g.pdf: Date accessed: May 17, 2005.
13. Finlay G.A., O'Driscoll L.R., Russell K.J., D'Arcy E.M., Masterson J.B., Fitzgerald M.X., and O'Connor C.M. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am. J. Respir. Crit. Care Med. 156 (1997) 240-247
14. Frisch S.M., and Morisaki J.H. Positive and negative transcriptional elements of the human type IV collagenase gene. Mol. Cell. Biol. 10 (1990) 6524
15. Gebel T.W. Arsenic methylation is a process of detoxification through accelerated excretion. Int. J. Hyg. Environ. Health 205 6 (2002) 505-508
16. Gong Z., Lu X., Cullen W.R., and Le X.C. Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid. J. Anal. At. Spectrom. 6 (2001) 1409-1413
17. Hinwood A.L., Sim M.R., de Klerk N., Drummer O., Gerostamoulos J., and Bastone E.B. Are 24-H urine samples and creatinine adjustment required for analysis of inorganic arsenic in urine in population studies?. Environ. Res. 88 (2002) 219-224
18. Hysong T.A., Burgess J.L., Cebrian Garcia M.E., and O'Rourke M.K. House dust and inorganic urinary arsenic in two Arizona mining towns. J. Expos. Anal. Environ. Epidemiol. 13 3 (2003) 211-218
19. Kanauchi M., Nishioka H., Nakashima Y., Hashimoto T., and Dohi K. Role of tissue inhibitors of metalloproteinase in diabetic nephropathy. Nippon Jinzo. Gakkai. Shi. 38 (1996) 124-128
20. Karagas M.R., Stukel T.A., Morris J.S., Tosteson T.D., Weiss J.E., Spencer S.K., and Greenberg E.R. Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. Am. J. Epidemiol. 153 (2001) 559-565
21. Kasahara A., Hayashi N., Mochizuki K., Oshita M., Katayama K., Kato M., Masuzawa M., Yoshihara H., Naito M., Miyamoto T., Inoue A., Asai A., Hijioka T., Fusamoto H., and Kamada T. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C-relationship to interferon reponse. J. Hepatol. 26 (1997) 574-583
22. Kumagai K., Ohno I., Okada S., Ohkawara Y., Suzuki K., Shinya T., Nagase H., Iwata K., and Shirato K. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J. Immunol. 162 (1999) 4212-4219
23. Lacraz S., Nicod L.P., Chicheportiche R., Welgus H.G., and Dayer J.M. Il-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest. 96 (1995) 2304-2310
24. Lamm S.H., Engel A., Kruse M.B., Feinleib M., Byrd D.M., Lai S., and Wilson R. Arsenic in drinking water and bladder cancer mortality in the US: an analysis based on 133 US counties and thirty years of observation. J. Occup. Med. 46 (2004) 298-306
25. Leppert D., Waubant E., Galardy R., Bunnett N.W., and Hauser S.L. T cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 154 (1995) 4379-4389
26. Lichtinghagen R., Huegel O., Seifert T., Haberkorn C.I., Michels D., Flemming P., Bahr M., and Boeker K.H.W. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin. Chem. 46 (2000) 183-192
27. Lim S., Roche N., Oliver B.G., Matos W., Barnes P.J., and Chung K.F. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers regulation by interleukin-10. Am. J. Respir. Crit. Care Med. 162 (2000) 1355-1360
28. Liu J., Liu Y.P., Goyer R.A., Achanzar W., and Waalkes M.P. Metallothionein-I-II null mice are more sensitive than wild-type mice to the hepatotoxic and nephrotoxic effects of chronic oral or injected inorganic arsenicals. Toxicol. Sci. 55 (2000) 460-467
29. Lohr S. Sampling: Design and Analysis (1999), Duxbury Press
30. Maxwell P.R., Timms P.M., Chandran S., and Gordon D. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type-1 diabetes. Diabet. Med. 18 (2001) 777-780
31. Mikheev M.I. WHO global project on biological monitoring of chemical exposure at the workplace. Int. Arch. Occup. Environ. Health 68 6 (1996) 387
32. Moore L.E., Lu M., and Smith A.H. Childhood cancer incidence and arsenic exposure in drinking water in Nevada. Arch. Environ. Health 57 (2002) 201-206
33. Moschandreas D.J., Karuchit S., Berry M.R., O'Rourke M.K., Lo D., Lebowitz M.D., and Robertson G. Exposure apportionment: ranking food items by their contribution to dietary exposure. J. Expos. Anal. Environ. Epidemiol. 12 4 (2002) 233-243
34. Murphy G., and Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol. 248 (1995) 496-510
35. Nagese H., and Woessner Jr. J.F. Matrix metalloproteinses. J. Biol. Chem. 274 (1999) 21491
36. O'Connell J.P., Willenbrock F., Docherty A.J., Eaton D., and Murphy G. Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. J. Biol. Chem. 27;269 21 (1994) 14967-14973
37. Ohnishi K., Takagi M., Kurokawa Y., Satomi S., and Konttinen Y.T. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab. Invest. 78 9 (1998) 1077-1087
38. Okada Y., Gonoji Y., Naka K., Tomita K., Nakanishi I., Iwata K., Yamashita K., and Hayakawa T. Matrix metalloproteinase 9 (92-kd gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells: purification and activation of the precursor and enzymic properties. J. Biol. Chem. 25 (1992) 21712-21719
39. Schwingshackl A., Duszyk M., Brown N., and Moqbel R. Human eosinophils release matrix metalloproteinase-9 on stimulation with TNF-alpha. Allergy Clin. Immunol. 104 (1990) 983
40. Signorelli S.S., Malaponte G., Libra M., Di Pino L., Celotta G., Bevelacqua V., Petrina M., Nicotra G.S., Indelicato M., Navolanic P.M., Pennisi G., and Mazzarino M.C. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc. Med. 10 (2005) 1-6
41. Steinmaus C., Yuan Y., Bates M.N., and Smith A.H. Case-control study of bladder cancer and drinking water arsenic in the western United States. Am. J. Epidemiol. 158 (2003) 1193-2001
42. Stetler-Stevenson W.G., Krutzsch H.C., and Liotta L.A. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J. Biol. Chem. 264 (1989) 17374-17378
43. Stratmann B., Farr M., and Tschesche H. MMP-TIMP interaction depends on residue 2 in TIMP-4. FEBS Lett. 2;507 3 (2001) 285-287
44. Styblo M., Del Razo L.M., Vega L., Germolec D.R., LeCluyse E.L., Hamilton G.A., Reed W., Wang C., Cullen W.R., and Thomas D.J. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch. Toxicol. 74 (2000) 289-299
45. Tanaka H., Miyazaki N., Oashi K., Tanaka S., Ohmichi M., and Abe S. Sputum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio in acute asthma. J. Allergy Clin. Immunol. 105 (2000) 900-905
46. Tashiro K., Koyanagi I., Ohara I., Ito T., Saitoh A., Horikoshi S., and Tomino Y. Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy. J. Clin. Lab. Anal. 18 (2004) 206-210
47. Vignola A.M., Riccobono L., Mirabella A., Profita M., Chanez P., Bellia V., Mautino G., D'Accardi P., Bousquet J., and Bonsignore G. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am. J. Respir. Crit. Care Med. 158 (1998) 1945-1950
48. von Ehrenstein O.S., Mazumder D.N.G., Yuan Y., Samanta S., Balmes J., Sil A., Ghosh N., Hira-Smith M., Haque R., Purushothamam R., Lahiri S., Das S., and Smith A.H. Decrements in lung function related to arsenic in drinking water in West Bengal, India. Am. J. Epidemiol. 162 (2005) 533-541
49. Wanibuchi H., Yamomoto S., Chen H., Yoshida K., Endo G., Hori T., and Fukushima S. Promoting effects of dimethyl arsenic acid on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in rats. Carcinogenesis 17 11 (1996) 2435-2439
50. Yamamoto S., Konishi Y., Matsuda T., Murai T., Shibata M.A., Matsui-Yuasa I., Otani S., Kuroda K., Endo G., and Fukushima S. Cancer Induction by an organic arsenic compound dimethylarsonic acid (cacodylic acid), in F344/DuCrj rats after pretreatment with five carcinogens. Cancer Res. 55 6 (1995) 1271-1276
51. Yamamoto S., Wanibuchi H., Hori T., Yano Y., Matsui-Yuasa I., Otani S., Chen H., Yoshida K., Kuroda K., Endo G., and Fukushima S. Possible carcinogenic potential of dimethylarsenic acid as assessed in rat in vivo models: a review. Mutat. Res. 386 3 (1997) 353-361
52. Yamanaka K., Hoshino M., Okamoto M., Sawamura R., Hasegawa A., and Okada S. Induction of DNA damage by dimethylarsine, a metabolite of inorganic arsenics, is for the major part likely due to its peroxyl radical. Biochem. Biophys. Res. Commun. 168 (1990) 58-64
53. Zhao C.Q., Young M.R., Diwan N.A., Coogan T.P., and Waalkes M.P. Association of arsenic induced malignant transformation with DNA hypo-methylation and aberrant gene expression. Proc. Natl. Acad. Sci. USA 94 (1997) 10907-10912